WO2006046252A2 - Novel diasteriomeric salts of atenolol and their use in the production of optically active atenolol - Google Patents

Novel diasteriomeric salts of atenolol and their use in the production of optically active atenolol Download PDF

Info

Publication number
WO2006046252A2
WO2006046252A2 PCT/IN2004/000335 IN2004000335W WO2006046252A2 WO 2006046252 A2 WO2006046252 A2 WO 2006046252A2 IN 2004000335 W IN2004000335 W IN 2004000335W WO 2006046252 A2 WO2006046252 A2 WO 2006046252A2
Authority
WO
WIPO (PCT)
Prior art keywords
atenolol
formula
propanol
isopropylamino
phenoxy
Prior art date
Application number
PCT/IN2004/000335
Other languages
French (fr)
Other versions
WO2006046252A3 (en
Inventor
Ashok Kumar
Ketan Dhansukhlal Vyas
Dharmendra Singh
Ganesh Devidas Mahale
Thankachan Byju Nellithanath
Sanjay Nandavadekar
Balasaheb Ganpat Jadhav
Ashvini Kumar Nand Kishore Saxena
Mehul Khodidas Darji
Anindya Bhattacharya
Ashish Lakhera
Original Assignee
Ipca Laboratories Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipca Laboratories Limited filed Critical Ipca Laboratories Limited
Priority to PCT/IN2004/000335 priority Critical patent/WO2006046252A2/en
Publication of WO2006046252A2 publication Critical patent/WO2006046252A2/en
Publication of WO2006046252A3 publication Critical patent/WO2006046252A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Definitions

  • the present invention relates to novel optically active atenolol tartrate salts, their use in the process for preparing optically active atenolol and a process for manufacturing the same.
  • Atenolol is useful as beta-adrenergic blocker for the treatment of angina pectoris, arrhythmia and hypertension. It is also known that atenolol has an 1 - aryloxy-3-aminopropan-2-ol nucleus wherein the hydroxy-bonded carbon is an asymmetric carbon and hence includes optical isomers, namely, R- and S-isomers (notation), and the S-isomer thereof is particularly useful as beta-adrenergic blocker in view of its superior pharmacological activities. It is reported that only S-isomer of atenolol has hypotensive activity and activity on brachycardia (cf. A. A. Pearson, T.E.
  • Atenolol is 4-[2-hydroxy-3-[(l-methylethyl)amino]propoxy] benzene acetamide and is represented by the structure Formula I( where * denotes the chiral carbon atom).
  • Atenolol was prepared by reacting 4-hydroxyphenylacetamide with epihalohydrin (e.g. epichlorohydrin) to obtain a glycidyl ether intermediate which is then reacted with isopropyl amine (Ref. U.S. Patent Nos. 3,663,607, 3,836,671 and 3,934,032).
  • epihalohydrin e.g. epichlorohydrin
  • Optically active atenolol was prepared by using an optically active epichlorohydrin in the process in place of racemic epichorohydrin.
  • an optically active epichlorohydrin if used, racemization occurs during its reaction with the 4-hydroxyphenylacetamide under basic conditions and hence, the optical purity of the intermediate glycidyl ether intermediate becomes less than 70 % ee resulting in the final product having less than 70 % ee.
  • this process requires a large amount of the expensive optically active epichlorohydrin for the formation of glycidyl ether, and even though the excess amount of epichlorohydrin can be recovered, it can not be reused because of its lower optical purity. Accordingly, this process is not suitable for producing an optically active atenolol and intermediate thereof, either.
  • a simple and direct method for separating racemates is by optical resolution which is carried out by reacting a racemic compound with a suitable optically active organic acid/base to form diatsteriomeric salts which have different crystallization characteristics followed by fractional crystallization. It has been studied to produce optically active atenolol by optical resolution but any practical method has not been reported for the same to the best of our knowledge.
  • the present inventors have intensively explored selective isolation of various diasterioisomeric salts of atenolol prepared by reaction with chiral acids in order to find a suitable process for simple isolation and purification of atenolol in optically pure form, and have found that the diasteriomeric tartaric acid salts can be prepared and used for separation of racemic atenolol into optical antipodes in higher enantiomeric purity.
  • the objective of the present invention is to provide novel diasteriomeric tartaric acid salts of atenolol and process for their preparation, and thereby to provide a method for industrially viable preparation of optically active S- atenolol, which function as a cure for essential hypertension, angina pectoris, and tachycardiac arhythmia.
  • the present invention discloses a novel diasteriomeric tartaric acid salts of atenolol namely, (2S)- 1 -isopropylamino-3-[4-(2-acetamido)phenoxy]-2-propanol-(2S,3S)- O,O-di-p-toluoyltartrate (Formula III) (2R)-l-isopropylamino-3-[p-(2- methoxyethyl)phenoxy]-2-propanol-(2R,3R)-O,O-di-p-toluoyltartrate( Formula V) and their use in the preparation of optically active atenolol.
  • the present invention discloses the use of above diasteriomeric tartrate salts of atenolol in the separation of S- and R-isomers of atenolol by a simple industrial racemic resolution.
  • the present invention further provides the process for the preparation of the above novel tartaric acid diasterioisomers of atenolol.
  • the racemic atenolol was reacted with (2S,3S)- 0,0-di-p-toluoyltartaric acid in a suitable inert solvent to crystallize out one of the diasteriomeric tartrate salt namely, (2S)-l-isopropylamino-3-[4-(2- acetamido)phenoxy]-2-propanol-(2S,3S)-O,O-di-p-toluoyltartrate, the latter on neutralization with base such as sodium hydroxide or potassium hydroxide generates S-atenolol.
  • the racemic atenolol was reacted with -(2R,3R)-O,O-di-p-toluoyltartaric acid in a suitable inert solvent to crystallize out one of the diasteriomeric tartrate salt namely, (2R)-l-isopropylamino-3-[4-(2- acetamido)phenoxy]-2-propanol-(2R,3R)-0,0-di-p-toluoyltartrate, from the solvent which is used to prepare R-atenolol by treating it with a suitable base such as sodium hydroxide, potassium hydroxide etc.
  • the suitable solvents used for the selective crystallization of above diasteriomeric salts include C] to C 4 alcohols or their mixture thereof or mixture of Ci to C 4 alcohols with hydrocarbon solvents such as n- hexane, cyclohexane, toluene, and ether solvents like diisopropyl ether, tetrahydrofuran etc.
  • the racemic diasteriomeric tartrate of atenolol is prepared in a suitable solvent like methanol at a temperature ranging from room temperature to reflux temperature and is selectively crystallized from the aforementioned crystallization solvents to give optically active tartaric acid salts of the present invention.
  • the present invention thus relates to the optical resolution of racemic atenolol into its enantiomers in substantially pure form.
  • Racemic atenolol hereinafter means atenolol containing identical quantities of optical antipodes (dextro and levorotatory isomers).
  • Optical resolution or separation, herein after, are synonymous and is a direct method of separation of pure enantiomers by reacting racemic compound with optically active acids/bases to form racemic diatsteriomeric salts which have different crystallization characteristics and can be separated by fractional crystallization using a suitable solvent followed by the liberation of the optically active enantiomer from its salt by neutralization.
  • optically active acids for the resolution of racemic atenolol are selected from the group consisting of (O,O)-di-p-toluoyltartaric acid, and (O,O)-di- benzoyl tartaric acid.
  • the optically active acid advantageously used in the present invention are (2R,3R)-(O,O)-di-p-toluoyltartaric acid and (2S,3S)-(O,O-di-p- toluoyl tartaric acid or their monohydrate solvates.
  • one and the same solvent may be used in the salt formation and subsequent fractional crystallization /recrystallizations.
  • the optically active ditoluoyltartaric acid of Formula II is allowed to react with racemic atenolol of Formula I in an inert solvent according to the following scheme.
  • the salt formation may be carried out in solvents such as alcohols, ketones, a mixture of alcohol and hydrocarbon solvents selected from hexane, cyclohexane, toluene, or a mixture of alcohol with ether solvents like diisopropyl ether, THF etc.
  • solvents such as alcohols, ketones, a mixture of alcohol and hydrocarbon solvents selected from hexane, cyclohexane, toluene, or a mixture of alcohol with ether solvents like diisopropyl ether, THF etc.
  • a mixture of two diasteriomers of Formula III and IV are formed in the reaction namely, (2S)-l-isopropylamino-3-[4-(2-acetamido)phenoxy]-2-propanol-(2S,3S)- O,O-di-p-toluoyltartrate and (2R)- 1 -isopropylamino-3-[4-(2-acetamido)phenoxy]-2- propanol-(2S,3S)-O,O-di-p-toluoyltartrate respectively, when (S 5 S) ditoluoyl tartaric acid is reacted with racemic atenolol.
  • the salt formation may be effected at ambient temperatures or at elevated temperatures.
  • the solvents advantageously used for the salt formation and selective crystallization of one of the diasteriomeric salt is selected from alcohols such as ethanol, isopropyl alcohol or a mixture of above alcohols with methanol or a mixture of Ci to C 4 alcohol with hydrocarbon solvents like hexane, cyclohexane, toluene or mixture of alcohols with ether solvents like diisopropylether, tetrahydrofuran.
  • the most preferred solvent is ethanol or isopropyl alcohol.
  • the individual diasteriomeric salt may be purified by repeated crystallization from the same or different solvent as described above to enrich one of the diasteriomer in pure form, if necessary.
  • the optical rotatory power of the precipitate is measured using a polarimeter at 2O 0 C in methanol at a concentration varying between 1.0 and 2g per 100ml.
  • the optical purity of the diasteriomer is also analyzed using HPLC with a chiral stationary column e.g. Chiropak*. Further, the diasteriomers are recrystallized, if required, to get a constant optical purity.
  • (2S)-l-isopropylamino-3-[4-(2-acetamido)phenoxy]-2-propanol- (2S,3S)-O,O-di-p-toluoyltartrate is prepared by reacting (2S,3S)-O,O-di-p- toluoyltartaric acid with racemic atenolol in ethanol at a temperature of 40 ° to 60 ° C for a period of 1 hour to effect complete salt formation.
  • the two diasteriomeric salts, Formula III and Formula IV so formed in the reaction mixture are then cooled to a temperature of 25 ° to 40 ° C in order to effect fractional crystallization of one of the diasteriomer.
  • the physico-chemical properties of this diasteriomer are as follows:
  • the FT Infrared absorption spectra of the (2S)-l-isopropylarnino-3-[4-(2- acetamido)phenoxy]-2-propanol-(2S,3 S)-O,O-di-p-toluoyltartrate showed the absorption at wavelength 3400 cm 2 , 1720 cm 2 , 1610 cm 2 , 1510 cm 2 , 1380 cm 2 , 1275 cm 2 , 1185 cm 2 , 1 110 cm 2 , 1055 cm 2 , 1020 cm 2 , 760cm 2 , 710cm 2 .
  • the delta values of the proton nuclear magnetic resonance spectra are ⁇ 1.1 (d 6H -(CH3) 2 ) , ⁇ 2.3(s 6H -CH3), ⁇ 3.0-3.2(m 2H N-CH2), ⁇ 3.3 (m IH N-CH), ⁇ 3.39 (s 2H -COCH2-), ⁇ 4.2(m IH -C- OH), ⁇ 5.7(s IH -CH), ⁇ 6.7(m3H NH Ar.), ⁇ 7.0(d 2H Ar), ⁇ 7.3 (dd 4H Ar), ⁇ 7.5(s IH -NH), ⁇ 7.8(dd 4H Ar), ⁇ 8.5(broad s -COOH).
  • the (2R)-I -isopropylamino-3-[p-(2-methoxy ethyl)phenoxy]-2-propanol-(2R,3R)- O,O-di-p-toluoyltartrate( Formula - V) of the present invention is prepared by reacting (-)-(2R,3R)-O,O-di-p-toluoyltartaric acid with racemic atenolol in ethanol at a temperature of 40 ° to 6O 0 C for a period of 1 to 3 hours to effect complete salt formation.
  • the two diasteriomeric salts namely, (2R)-l-isopropylamino-3-[4-(2- acetamido)phenoxy]-2-propanol-(2R,3R)-O,O-di-p-toluoyl tartrate and (2S)-I- isopropylamino-3-[4-(2-acetamido)phenoxy]-2-propanol-(2R,3R)-O,O-di-p- toluoyltartrate, so formed in the reaction mixture is then cooled to a temperature of 35° to 40° C in order to effect fractional crystallization of one of the diasteriomer.
  • the delta values of the proton nuclear magnetic resonance spectra are ⁇ l.l(d 6H -(CH3) 2 ) , ⁇ 2.3(s 6H -CH3), ⁇ 3.0-3.2(m 2H N-CH2), 63.3 (m IH N-CH), ⁇ 3.39 (s 2H -COCH2-), ⁇ 4.2(m IH -C- OH), ⁇ 5.7(s IH -CH), ⁇ 6.7(m3H NH Ar.), ⁇ 7.0(d 2H Ar), 67.3 (dd 4H Ar), ⁇ 7.5(s IH -NH), ⁇ 7.8(dd 4H Ar), ⁇ 8.5(broad s -COOH).
  • optically active atenolol tartrate salts of the invention are easily hydrolyzed with a base such as sodium hydroxide or potassium hydroxide in a solvent like water to yield optically active atenolol.
  • the pure isomers of atenolol is prepared by the action of a base such as sodium hydroxide or sodium carbonates with the optically active diasteriomeric tatrate salts of the present invention in aqueous media at temperatures ranging between 10 to 30 0 C
  • R- Atenolol (dextro rotatory) is prepared from (2R)-l-isopropylamino- 3-[4-(2-acetamido)phenoxy]-2-propanol-(2R,3R)-O,O-di-benzoyltartrate and, the S- Atenolol (levo rotatory) is prepared from (2S)-l-isopropylamino-3-[4-(2- acetamido)phenoxy]-2-propanol-(2S,3S)-O,O-di-benzoyltartrate by neutralization using sodium hydroxide in aqueous media to precipitate the required enantiomer.
  • racemic diaterioisomeric salts of tartaric acid may be prepared separately into a solvent such as methanol by conducting the reaction of racemic atenolol with tartaric acid derivative used in the present invention in the said solvents and isolating as a mixture of two diasteriomers by solvent evaporation.
  • a solvent such as methanol
  • the mixture of two diasteriomers e.g.
  • the suitable conditions are such that the mixture of diasterioisomers are dissolved in suitable solvent at ambient temperature or elevated temperature and cooling/chilling to yield crystals of one of the diasteriomer in substantially pure form.
  • the delta values of the proton nuclear magnetic resonance spectra are ⁇ l.l(d 6H -(CH3) 2 ) , ⁇ 2.3(s 6H -CH3), ⁇ 3.0-3.2(m 2H N-CH2), 53.3 (m IH N-CH), ⁇ 3.39 (s 2H -COCH2-), ⁇ 4.2(m IH -C- OH), ⁇ 5.7(s IH -CH), ⁇ 6.7(m3H NH Ar.), ⁇ 7.0(d 2H Ar), ⁇ 7.3 (dd 4H Ar), ⁇ 7.5(s IH -NH), ⁇ 7.8(dd 4H Ar), ⁇ 8.5(broad s -COOH).
  • the delta values of the proton nuclear magnetic resonance spectra are ⁇ l.l(d 6H -(CH3) 2 ) , ⁇ 2.3(s 6H -CH3), ⁇ 3.0-3.2(m 2H N-CH2), 53.3 (m IH N-CH), ⁇ 3.39 (s 2H -COCH2-), ⁇ 4.2(m IH -C- OH), ⁇ 5.7(s IH -CH), ⁇ 6.7(m3H NH Ar.), ⁇ 7.0(d 2H Ar), 57.3 (dd 4H Ar), ⁇ 7.5(s IH -NH), ⁇ 7.8(dd 4H Ar), ⁇ 8.5(broad s -COOH).

Abstract

Novel diasteriomeric tartaric acid salts of atenolol namely, (2S)-1-isopropylamino-3-[4-(2-acetamido)phenoxy]-2-propanol-(2S,3S)-O,O-di-p-toluoyltartrate, (2R)-1­isopropylamino-3-[p-(2-methoxyethyl)phenoxy]-2-propanol-(2R,3R)-O,O-di-p-toluoyltartrate and their use in the preparation of optically active atenolol by a simple industrial racemic resolution is disclosed herein.

Description

Field of the Invention
The present invention relates to novel optically active atenolol tartrate salts, their use in the process for preparing optically active atenolol and a process for manufacturing the same.
Background of the invention
It is known that atenolol is useful as beta-adrenergic blocker for the treatment of angina pectoris, arrhythmia and hypertension. It is also known that atenolol has an 1 - aryloxy-3-aminopropan-2-ol nucleus wherein the hydroxy-bonded carbon is an asymmetric carbon and hence includes optical isomers, namely, R- and S-isomers (notation), and the S-isomer thereof is particularly useful as beta-adrenergic blocker in view of its superior pharmacological activities. It is reported that only S-isomer of atenolol has hypotensive activity and activity on brachycardia (cf. A. A. Pearson, T.E. Gaffney, T. Walle, P.J. Privhera; J. Pharmacol. Exp.Ther., 250 (3), 759, 1989). The chemical name of atenolol is 4-[2-hydroxy-3-[(l-methylethyl)amino]propoxy] benzene acetamide and is represented by the structure Formula I( where * denotes the chiral carbon atom).
Figure imgf000002_0001
Formula I
While racemic atenolol is presently marketed widely for the treatment of hypertension, angina, and has shown to promise in the treatment of post myocardial infraction, the S-isomer is found to avoid the occasional side effect of a lowered heart rate sometimes encountered with the racemate( racemic atenolol). It is therefore important to develop an industrial method for the preparation of S-atenolol. Atenolol was prepared by reacting 4-hydroxyphenylacetamide with epihalohydrin (e.g. epichlorohydrin) to obtain a glycidyl ether intermediate which is then reacted with isopropyl amine (Ref. U.S. Patent Nos. 3,663,607, 3,836,671 and 3,934,032).
Optically active atenolol was prepared by using an optically active epichlorohydrin in the process in place of racemic epichorohydrin. However, according this process, if an optically active epichlorohydrin is used, racemization occurs during its reaction with the 4-hydroxyphenylacetamide under basic conditions and hence, the optical purity of the intermediate glycidyl ether intermediate becomes less than 70 % ee resulting in the final product having less than 70 % ee. Moreover, this process requires a large amount of the expensive optically active epichlorohydrin for the formation of glycidyl ether, and even though the excess amount of epichlorohydrin can be recovered, it can not be reused because of its lower optical purity. Accordingly, this process is not suitable for producing an optically active atenolol and intermediate thereof, either.
A simple and direct method for separating racemates is by optical resolution which is carried out by reacting a racemic compound with a suitable optically active organic acid/base to form diatsteriomeric salts which have different crystallization characteristics followed by fractional crystallization. It has been studied to produce optically active atenolol by optical resolution but any practical method has not been reported for the same to the best of our knowledge.
It is reported that S-atenolol having a high optical purity is obtained from the racemic mixture by derivatisation of racemic atenolol using (R,R)-O,O-di-p- toluoyltartaric acid anhydride to give a mixture of diasteriomeric tartaric acid monoesters (ref- Wilson M.J. et al., J. Chromatogr. (NLD) 431 (1), 222-227, 1988 and United States patent US4652672). However, this method of derivatisation requires troublesome extraction, a number of stages to obtain free optically active atenolol and also requires a large amount of solvent apart from being non-attractive , from the view point of recovery and recyclability of (R,R)-0,0-di-p-toluoyl-tartaric acid anhydride, and hence, this method is not suitable for the practical production of optically active atenolol.
Another process on derivatization based optical resolution of atenolol was reported in US patent 4463176. This process comprised of; reaction of atenolol with a chiral isocyanate compound to obtain diasteriomeric urea derivatives; separation of the resulting diastariomers into its optical antipodes and regenerating optically active atenolol. This method also suffers from the point of view of industrial applicability as it involves number of stages, troublesome purification procedures. Since the recycling of chiral isocyanate compound is also not technically feasible, it leads to escalation of the cost of production thus the process is uneconomical.
The present inventors have intensively explored selective isolation of various diasterioisomeric salts of atenolol prepared by reaction with chiral acids in order to find a suitable process for simple isolation and purification of atenolol in optically pure form, and have found that the diasteriomeric tartaric acid salts can be prepared and used for separation of racemic atenolol into optical antipodes in higher enantiomeric purity.
Objective of the present invention
The objective of the present invention is to provide novel diasteriomeric tartaric acid salts of atenolol and process for their preparation, and thereby to provide a method for industrially viable preparation of optically active S- atenolol, which function as a cure for essential hypertension, angina pectoris, and tachycardiac arhythmia. Summary of the invention
The present invention discloses a novel diasteriomeric tartaric acid salts of atenolol namely, (2S)- 1 -isopropylamino-3-[4-(2-acetamido)phenoxy]-2-propanol-(2S,3S)- O,O-di-p-toluoyltartrate (Formula III) (2R)-l-isopropylamino-3-[p-(2- methoxyethyl)phenoxy]-2-propanol-(2R,3R)-O,O-di-p-toluoyltartrate( Formula V) and their use in the preparation of optically active atenolol.
Accordingly, the present invention discloses the use of above diasteriomeric tartrate salts of atenolol in the separation of S- and R-isomers of atenolol by a simple industrial racemic resolution.
The present invention further provides the process for the preparation of the above novel tartaric acid diasterioisomers of atenolol.
In one embodiment of the invention, the racemic atenolol was reacted with (2S,3S)- 0,0-di-p-toluoyltartaric acid in a suitable inert solvent to crystallize out one of the diasteriomeric tartrate salt namely, (2S)-l-isopropylamino-3-[4-(2- acetamido)phenoxy]-2-propanol-(2S,3S)-O,O-di-p-toluoyltartrate, the latter on neutralization with base such as sodium hydroxide or potassium hydroxide generates S-atenolol.
In another embodiment of the present invention the racemic atenolol was reacted with -(2R,3R)-O,O-di-p-toluoyltartaric acid in a suitable inert solvent to crystallize out one of the diasteriomeric tartrate salt namely, (2R)-l-isopropylamino-3-[4-(2- acetamido)phenoxy]-2-propanol-(2R,3R)-0,0-di-p-toluoyltartrate, from the solvent which is used to prepare R-atenolol by treating it with a suitable base such as sodium hydroxide, potassium hydroxide etc.. In the process of the present invention, the suitable solvents used for the selective crystallization of above diasteriomeric salts include C] to C4 alcohols or their mixture thereof or mixture of Ci to C4 alcohols with hydrocarbon solvents such as n- hexane, cyclohexane, toluene, and ether solvents like diisopropyl ether, tetrahydrofuran etc.
In yet another embodiment of the present invention, the racemic diasteriomeric tartrate of atenolol is prepared in a suitable solvent like methanol at a temperature ranging from room temperature to reflux temperature and is selectively crystallized from the aforementioned crystallization solvents to give optically active tartaric acid salts of the present invention.
Detailed description of the present invention
The present invention thus relates to the optical resolution of racemic atenolol into its enantiomers in substantially pure form. Racemic atenolol hereinafter means atenolol containing identical quantities of optical antipodes (dextro and levorotatory isomers). Optical resolution or separation, herein after, are synonymous and is a direct method of separation of pure enantiomers by reacting racemic compound with optically active acids/bases to form racemic diatsteriomeric salts which have different crystallization characteristics and can be separated by fractional crystallization using a suitable solvent followed by the liberation of the optically active enantiomer from its salt by neutralization.
Accordingly, the optically active acids for the resolution of racemic atenolol are selected from the group consisting of (O,O)-di-p-toluoyltartaric acid, and (O,O)-di- benzoyl tartaric acid. The optically active acid advantageously used in the present invention are (2R,3R)-(O,O)-di-p-toluoyltartaric acid and (2S,3S)-(O,O-di-p- toluoyl tartaric acid or their monohydrate solvates.
The resultant diasterioisomers namely, (2S)-l-isopropylamino-3-[4-(2- acetamido)phenoxy]-2-propanol-(2S,3S)-O,O-di-p-toluoyltartrate,(Formula - III ) and (2R)-l-isopropylamino-3-[p-(2-methoxyethyl) phenoxy]-2-propanol-(2R,3R)- 0,0-di-p-toluoyltartrate ( Formula - V) are not known in the literature or prepared earlier and are parts of the present invention.
In the process of the present invention, one and the same solvent may be used in the salt formation and subsequent fractional crystallization /recrystallizations. In the process of the present invention, according to a general preparative method, the optically active ditoluoyltartaric acid of Formula II is allowed to react with racemic atenolol of Formula I in an inert solvent according to the following scheme.
Figure imgf000008_0001
The salt formation may be carried out in solvents such as alcohols, ketones, a mixture of alcohol and hydrocarbon solvents selected from hexane, cyclohexane, toluene, or a mixture of alcohol with ether solvents like diisopropyl ether, THF etc. A mixture of two diasteriomers of Formula III and IV are formed in the reaction namely, (2S)-l-isopropylamino-3-[4-(2-acetamido)phenoxy]-2-propanol-(2S,3S)- O,O-di-p-toluoyltartrate and (2R)- 1 -isopropylamino-3-[4-(2-acetamido)phenoxy]-2- propanol-(2S,3S)-O,O-di-p-toluoyltartrate respectively, when (S5S) ditoluoyl tartaric acid is reacted with racemic atenolol. The (2S)-l-isopropylamino-3-[4-(2- acetamido)phenoxy]-2-propanol-(2S,3S)-O,O-di-p-toluoyltartrate isomer selectively crystallized from suitable crystallizing solvent and the (2R)-l-isopropylamino-3-[4- (2-acetamido)phenoxy]-2-propanol-(2S,3S)-O,O-di-p-toluoyltartrate isomer remain in mother liquor.. The salt formation may be effected at ambient temperatures or at elevated temperatures.
The solvents advantageously used for the salt formation and selective crystallization of one of the diasteriomeric salt is selected from alcohols such as ethanol, isopropyl alcohol or a mixture of above alcohols with methanol or a mixture of Ci to C4 alcohol with hydrocarbon solvents like hexane, cyclohexane, toluene or mixture of alcohols with ether solvents like diisopropylether, tetrahydrofuran. The most preferred solvent is ethanol or isopropyl alcohol.
The individual diasteriomeric salt may be purified by repeated crystallization from the same or different solvent as described above to enrich one of the diasteriomer in pure form, if necessary. After each crystallization, the optical rotatory power of the precipitate is measured using a polarimeter at 2O0C in methanol at a concentration varying between 1.0 and 2g per 100ml. The optical purity of the diasteriomer is also analyzed using HPLC with a chiral stationary column e.g. Chiropak*. Further, the diasteriomers are recrystallized, if required, to get a constant optical purity. (* trade name) In the process of the invention, preferably one molar equivalent of the (O,O)ditoluoyltartaric acid is mixed with racemic atenolol during the salt formation stage. The salt formation is advantageously effected at a temperature ranging from 25° to 75° C and most preferably in the temperature range of 40° to 60° C.
Consequently, (2S)-l-isopropylamino-3-[4-(2-acetamido)phenoxy]-2-propanol- (2S,3S)-O,O-di-p-toluoyltartrate is prepared by reacting (2S,3S)-O,O-di-p- toluoyltartaric acid with racemic atenolol in ethanol at a temperature of 40 ° to 60 ° C for a period of 1 hour to effect complete salt formation. The two diasteriomeric salts, Formula III and Formula IV so formed in the reaction mixture are then cooled to a temperature of 25 ° to 40 ° C in order to effect fractional crystallization of one of the diasteriomer. The precipitated (2S)-l-isopropylamino-3-[4-(2- acetamido)phenoxy]-2-propanol-(2S,3S)-O,O-di-p-toluoyltartrate (Formula III) is filtered off and dried in an oven to give white crystals having a melting point between 150.9 to 151.50C. The specific rotation is measured as +79.9 ° to +81° (1.0 % methanol at 20° C)
The physico-chemical properties of this diasteriomer are as follows: The FT Infrared absorption spectra of the (2S)-l-isopropylarnino-3-[4-(2- acetamido)phenoxy]-2-propanol-(2S,3 S)-O,O-di-p-toluoyltartrate showed the absorption at wavelength 3400 cm2, 1720 cm2, 1610 cm2, 1510 cm2, 1380 cm2, 1275 cm2, 1185 cm2, 1 110 cm2, 1055 cm2, 1020 cm2, 760cm2, 710cm2 .
The delta values of the proton nuclear magnetic resonance spectra (Instrument: Brucker - 400MHz, Solvent DMSOd6) are δ 1.1 (d 6H -(CH3)2) , δ2.3(s 6H -CH3), δ3.0-3.2(m 2H N-CH2), δ3.3 (m IH N-CH), δ 3.39 (s 2H -COCH2-), δ4.2(m IH -C- OH), δ5.7(s IH -CH), δ6.7(m3H NH Ar.), δ 7.0(d 2H Ar), δ7.3 (dd 4H Ar), δ 7.5(s IH -NH), δ7.8(dd 4H Ar), δ 8.5(broad s -COOH). Moreover, the result of the elemental analysis was 61.1% C, 5.97% H and 4.2%N and 28.71 % O and the rational Formula of the resultant compound is determined to be C34H40N2O12 as calculated values Of C34H4ON2Oi2 agrees with 61.07% C, 5.92% H and 4.19% N and 28.74% O.
The (2R)-I -isopropylamino-3-[p-(2-methoxy ethyl)phenoxy]-2-propanol-(2R,3R)- O,O-di-p-toluoyltartrate( Formula - V) of the present invention is prepared by reacting (-)-(2R,3R)-O,O-di-p-toluoyltartaric acid with racemic atenolol in ethanol at a temperature of 40 ° to 6O0C for a period of 1 to 3 hours to effect complete salt formation. The two diasteriomeric salts namely, (2R)-l-isopropylamino-3-[4-(2- acetamido)phenoxy]-2-propanol-(2R,3R)-O,O-di-p-toluoyl tartrate and (2S)-I- isopropylamino-3-[4-(2-acetamido)phenoxy]-2-propanol-(2R,3R)-O,O-di-p- toluoyltartrate, so formed in the reaction mixture is then cooled to a temperature of 35° to 40° C in order to effect fractional crystallization of one of the diasteriomer. The precipitated (2R)-I -isopropylamino-3-[4-(2-acetamido)phenoxy]-2-propanol- (2R,3R)-O,O-di-p-toluoyltartrate is filtered off and dried in an oven to give white crystals having a melting point between 144.1 to 149.O0C. The specific rotation is measured as -76.5 (1.0 % methanol at 20° C).
Figure imgf000011_0001
Formula V The physico-chemical properties of this diasteriomer are as follows: The FT Infrared absorption spectra of the (2R)-l-isopropylamino-3-[4-(2- acetamido)phenoxy]-2-propanol-(2R,3R)-0,0-di-p-toluoyltartrate showed the absorption at wavelength 3400 cm2, 1720 cm2, 1610 cm2, 1510 cm2, 1380 cm2, 1275 cm2, 1185 cm2, 1110 cm2, 1055 cm2, 1020 cm2, 760cm2, 710cm2 .
The delta values of the proton nuclear magnetic resonance spectra (Instrument: Brucker - 400MHz, Solvent DMSOd6) are δl.l(d 6H -(CH3)2) , δ2.3(s 6H -CH3), δ3.0-3.2(m 2H N-CH2), 63.3 (m IH N-CH), δ 3.39 (s 2H -COCH2-), δ4.2(m IH -C- OH), δ5.7(s IH -CH), δ6.7(m3H NH Ar.), δ 7.0(d 2H Ar), 67.3 (dd 4H Ar), δ 7.5(s IH -NH), δ7.8(dd 4H Ar), δ 8.5(broad s -COOH).
Moreover, the result of the elemental analysis was 61.1% C, 5.97% H and 4.2%N and 28.71 % O and the rational Formula of the resultant compound is determined to be C34H40N2Oi2 as calculated values Of C34H40N2Oi2 agrees with 61.07% C, 5.92% H and 4.19% N and 28.74% O.
These optically active atenolol tartrate salts of the invention are easily hydrolyzed with a base such as sodium hydroxide or potassium hydroxide in a solvent like water to yield optically active atenolol.
Therefore, the pure isomers of atenolol is prepared by the action of a base such as sodium hydroxide or sodium carbonates with the optically active diasteriomeric tatrate salts of the present invention in aqueous media at temperatures ranging between 10 to 30 0C
Consequently, R- Atenolol (dextro rotatory) is prepared from (2R)-l-isopropylamino- 3-[4-(2-acetamido)phenoxy]-2-propanol-(2R,3R)-O,O-di-benzoyltartrate and, the S- Atenolol (levo rotatory) is prepared from (2S)-l-isopropylamino-3-[4-(2- acetamido)phenoxy]-2-propanol-(2S,3S)-O,O-di-benzoyltartrate by neutralization using sodium hydroxide in aqueous media to precipitate the required enantiomer.
The pure enantiomers of atenolol are isolated by normal work-up procedures like precipitation or extraction etc.
Alternately, the racemic diaterioisomeric salts of tartaric acid may be prepared separately into a solvent such as methanol by conducting the reaction of racemic atenolol with tartaric acid derivative used in the present invention in the said solvents and isolating as a mixture of two diasteriomers by solvent evaporation. For example, the mixture of two diasteriomers, e.g. (2R)-l-isopropylamino-3-[4-(2- acetamido)phenoxy]-2-propanol-(2R,3R)-O,O-di-p-toluoyltartrate and (2S)- 1 - isopropylamino-3-[4-(2-acetamido)phenoxy]-2-propanol-(2R,3R)-O,O-di-p-toluoyl tartrate formed by the reaction of racemic atenolol with (-)-(2R,3R)-O,O-di-p- toluoyltartaric acid, are separated by fractional crystallization from the solvents described hereinbefore. The suitable conditions are such that the mixture of diasterioisomers are dissolved in suitable solvent at ambient temperature or elevated temperature and cooling/chilling to yield crystals of one of the diasteriomer in substantially pure form.
The invention is further illustrated with the following actual examples and is not intended to be limiting in any manner to the scope of the invention as substantially described.
Examples
Example 1
(2S)-I -isopropylamino-3-[4-(2-acetamido)phenoxy]-2-propanol-(2S, 3S)-O, O-di-p- toluoyltartrate Atenolol (racemic) 100 gm. in 2 litres of ethanol and (+)-(2S,3S)-O,O-di-p- toluoyltartaric acid (120 gm.) was heated to 60 to 65 ° C for 3 hours. The mixture was then cooled to 30 ° C and maintained for 2 hours under stirring. The precipitated crystals are filtered off and dried to give 101 gm of (2S)-l-isopropylamino-3-[4-(2- acetamido)phenoxy]-2-propanol-(2S,3S)-O,O-di-p-toluoyltartrate. Optical purity 98% (chiral HPLC, Chiropack* column) and specific rotation +80 ° (c =1.0% in methanol)
The delta values of the proton nuclear magnetic resonance spectra (Instrument: Brucker - 400MHz5 Solvent DMSOd6) are δl.l(d 6H -(CH3)2) , δ2.3(s 6H -CH3), δ3.0-3.2(m 2H N-CH2), 53.3 (m IH N-CH), δ 3.39 (s 2H -COCH2-), δ4.2(m IH -C- OH), δ5.7(s IH -CH), δ6.7(m3H NH Ar.), δ 7.0(d 2H Ar), δ7.3 (dd 4H Ar), δ 7.5(s IH -NH), δ7.8(dd 4H Ar), δ 8.5(broad s -COOH).
Example 2
(2R)-l-isopropylamino-3-[4-(2-acetamido)phenoxy]-2-propanol-(2R,3R)-O,O-di-p- toluoyltartrate
Atenolol (racemic) 100 gm. in 2 litres of ethanol and (-)-(2R,3R)-O,O-di-p- toluoyltartaric acid (120 gm.) was heated to 60 to 650C for 3 hours. The mixture was then cooled to 30 ° C and maintained for 2 hours under stirring.The precipitated crystals are filtered off and dried to give 101 gm of (2R)-l-isopropylamino-3-[4-(2- acetamido)ρhenoxy]-2-propanol-(2R,3R)-O,O-di-p-toluoyltartrate. Optical purity 98% (chiral HPLC, Chiropack* column) and Specific rotation -76.5 ° (c= 1.0% in methanol)
The delta values of the proton nuclear magnetic resonance spectra (Instrument: Brucker - 400MHz, Solvent DMSOd6) are δl.l(d 6H -(CH3)2) , δ2.3(s 6H -CH3), δ3.0-3.2(m 2H N-CH2), 53.3 (m IH N-CH), δ 3.39 (s 2H -COCH2-), δ4.2(m IH -C- OH), δ5.7(s IH -CH), δ6.7(m3H NH Ar.), δ 7.0(d 2H Ar), 57.3 (dd 4H Ar), δ 7.5(s IH -NH), δ7.8(dd 4H Ar), δ 8.5(broad s -COOH).
Example 3 S-atenolol
The (2S)-l-isopropylamino-3-[4-(2-acetamido)phenoxy]-2-propanol-(2S,3S)-0,0- di-p-toluoyl tartrate obtained as in example 1 (101 gm) was mixed with 400 ml water in a reaction vessel and NaOH solution (100 gm in 100 water) was added dropwise. The reaction mixture was stirred for 2 hours at 10 to 15 0C. The precipitate was filtered and washed with cold water. The S-atenolol obtained is dried at 70 ° C to give 34 gm optically pure S-atenolol
Example 4 R-atenolol
The (2R)-l-isopropylamino-3-[4-(2-acetamido)phenoxy]-2-propanol-(2R,3R)-O,O- di-p-toluoyl tartrate obtained as in example 2 (101 gm) was mixed with 400 ml water in a reaction vessel and NaOH solution (100 gm in 100 water) was added dropwise. The reaction mixture was stirred for 2 hours at 10 to 15 0C. The precipitate was filtered and washed with cold water. The R-atenolol obtained is dried at 70 ° C to give 35 gm optically pure R-atenolol

Claims

We claim,
1. (2S)-I -isopropylamino-3-[4-(2-acetamido)phenoxy]-2-propanol-(2S,3S)-0,0-di- p-toluoyl tartrate of Formula IH in substantially optically active form
Formula III
Figure imgf000016_0001
2. (2R)- 1 -isopropylamino-3 - [4-(2-acetamido)phenoxy] -2-propanol-(2R,3 R)-0 ,0- di-p-toluoyl tartrate of Formula V in substantially optically active form
Formula V
Figure imgf000016_0002
3. A process for the preparation of Compound of Formula III claimed in claim 1 comprising: treating atenolol containing both optical isomers with (+)-(2S,3S)- O,O-di-p-toluoyl tartaric acid in a solvent to produce a mixture of diasteriomeric salts; and fractionally crystallizing compound of Formula III from the said salts in a suitable solvent in substantially optically pure form.
4. A process for the preparation of Compound of Formula V claimed in claim 2 comprising: treating atenolol containing both optical isomers with (+)-(2R,3R)- O,O-di-p-toluoyl tartaric acid in a solvent to produce a mixture of diasterimeric salts; and fractionally crystallizing compound of Formula V from the said salts in a suitable solvent in substantially optically pure form.
5. A process according to claim 3 or 4, wherein the salt forming and crystallizing/recrystallizing solvents are same.
6. A process according to claim 3 or 4, wherein the solvents for fractional crystallization of Formula III or V is selected independently from Q to C4 alcohol, mixture of Ci to C4 alcohols, mixture of Cl to C4 alcohols with hydrocarbon solvents such as hexane, cyclohexane, toluene, or a mixture of
• alcohol with ether solvents like diisopropyl ether, THF, and ethyl acetate.
7. A process according to claim 3 further comprising reacting compound of Formula III with a base to produce levorotatory atenolol (S-atenolol) substantially free of R-atenolol.
8. A process according to claim 4 further comprising reacting compound of Formula V with a base to produce dextrorotatory atenolol (R-atenolol) substantially free of S-atenolol.
9. A process according to claim 7 or 8, wherein the base is selected from inorganic bases like alkali metal carbonates or alkali metal hydroxides.
10. A process according to claim 9, wherein the reaction is performed in aqueous medium.
11. A process according to any one of the claim 7 to 10 wherein the reaction is performed in water.
12. (2S)-l-isopropylamino-3-[4-(2-acetamido)phenoxy]-2-propanol-(2S,3S)-0,0-di- p-toluoyl tartrate of Formula III and (2R)-l-isopropylamino-3-[4-(2- acetamido)phenoxy]-2-propanol-(2R,3R)-0,0-di-p-toluoyl tartrate of Formula V and the processes for preparation of said salts and its derivatives S-atenolol and R-atenolol as substantially described herein with reference to the foregoing examples 1 to 4.
PCT/IN2004/000335 2004-10-26 2004-10-26 Novel diasteriomeric salts of atenolol and their use in the production of optically active atenolol WO2006046252A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/IN2004/000335 WO2006046252A2 (en) 2004-10-26 2004-10-26 Novel diasteriomeric salts of atenolol and their use in the production of optically active atenolol

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IN2004/000335 WO2006046252A2 (en) 2004-10-26 2004-10-26 Novel diasteriomeric salts of atenolol and their use in the production of optically active atenolol

Publications (2)

Publication Number Publication Date
WO2006046252A2 true WO2006046252A2 (en) 2006-05-04
WO2006046252A3 WO2006046252A3 (en) 2007-07-12

Family

ID=36228174

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2004/000335 WO2006046252A2 (en) 2004-10-26 2004-10-26 Novel diasteriomeric salts of atenolol and their use in the production of optically active atenolol

Country Status (1)

Country Link
WO (1) WO2006046252A2 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0435068A2 (en) * 1989-12-27 1991-07-03 Daiso Co., Ltd. Process for producing optically active atenolol and intermediate thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0435068A2 (en) * 1989-12-27 1991-07-03 Daiso Co., Ltd. Process for producing optically active atenolol and intermediate thereof

Also Published As

Publication number Publication date
WO2006046252A3 (en) 2007-07-12

Similar Documents

Publication Publication Date Title
CA2623355C (en) Resolution of .alpha.-(phenoxy) phenylacetic acid derivatives with naphthyl-alkylamines
US11897843B2 (en) Process for the preparation of enantiomerically enriched 3-aminopiperidine
EP2067768A1 (en) A process for the preparation of (S)(+)-3-(aminomethyl)-5-methylhexanoic acid
EP0435068B1 (en) Process for producing optically active atenolol and intermediate thereof
IE920307A1 (en) Precipitation-induced asymmetric transformation of chiral¹alpha-amino acids and salts thereof
WO2010021093A1 (en) Asymmetric organic catalyst
JP2006028154A (en) Method for producing optically active compound
US4571424A (en) Optical resolution of racemic femoxetine
WO1997045431A1 (en) Optical resolution of narwedine-type compounds
WO2006046252A2 (en) Novel diasteriomeric salts of atenolol and their use in the production of optically active atenolol
US6479702B1 (en) 3-amino-1-indanole, method of synthesizing the same and method of optical resolution
US7238839B2 (en) Process for the resolution of racemic (R,S) -5-(2-(2-(2- ethoxyphenoxy) ethylamino)Propyl)-2-methoxybenzene sulfonamide (tamsulosin), its novel R and S isomers and their salts and processes for their preparation
EP1489066B1 (en) Process for production of optically active carboxylic acid
US5223646A (en) Process for producing optically active atenolol and intermediate thereof
EP0902011B1 (en) Gamma-oxo-homophenylalanine derivatives and process for producing homophenylalanine derivatives by reducing the same
WO1990008126A1 (en) Resolution process
JP2002332277A (en) Method for manufacturing optically active 2- methylpiperazine
JP2002371060A (en) Method for producing optically active aminopiperidine derivative
WO2002022543A1 (en) Process for preparing optically active carboxylic acid derivative
CA2157938C (en) Process for producing optically active atenolol and intermediate thereof
WO2001017944A1 (en) Process for producing optically active aminoalcohol
EP1853545B1 (en) Process for obtaining enantiomers of chrysanthemic acid
JP2003095991A (en) Method for producing optically active 3,3,3-trifluoro-2- hydroxy-2-methylpropionic acid
US20070010691A1 (en) Enantioselective synthesis of enantiomerically enriched compounds

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GE GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MK MN MW MX MZ NA NI NO NZ PG PH PL PT RO RU SC SD SE SG SK SY TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SZ TZ UG ZM ZW AM AZ BY KG MD RU TJ TM AT BE BG CH CY DE DK EE ES FI FR GB GR HU IE IT MC NL PL PT RO SE SI SK TR BF CF CG CI CM GA GN GQ GW ML MR SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 416/MUMNP/2007

Country of ref document: IN

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 04821387

Country of ref document: EP

Kind code of ref document: A2